TG-1000 clinical trials
Also written TG-1000.
How each study uses TG-1000 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TG-1000 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
TaiGen Biotechnology Co., Ltd. (2) · Boryung Biopharma Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test TG-1000, phase 3 first.
- Apr 2027A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaPhase 3 · Boryung Biopharma Co., Ltd.
Studies
Open first, then newest update. How each study uses TG-1000 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaRecruitingPhase 3Boryung Biopharma Co., Ltd.NCT07943390Written as BRC-201
- To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus InfectionCompletedPhase 2TaiGen Biotechnology Co., Ltd.NCT04706468Written as TG-1000
- To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.CompletedPhase 1TaiGen Biotechnology Co., Ltd.NCT04495322Written as TG-1000
What changed recently
From the registry's own updates since Oct 18, 2026.